Each September, the National Alliance on Mental Illness marks Suicide Prevention Month with campaigns built around a simple idea: talking about suicide openly saves lives. That idea holds up, because awareness reduces stigma, and stigma is one of the reasons people wait.
The harder question sits just past the conversation. When someone finally says out loud that they are thinking about ending their life, how quickly can care reach them? Tens of thousands of people die by suicide in the United States each year, according to the CDC’s suicide data and statistics, and many had been in contact with the health system in the months before. Awareness opens a door, and what matters next is how long a person has to stand in it.
If you or someone you love is in immediate danger, call or text 988 to reach the 988 Suicide & Crisis Lifeline, available 24 hours a day.
Why the timing of relief matters
Most first-line treatments for depression work slowly. Selective serotonin reuptake inhibitors and similar medications generally take several weeks to show a meaningful effect, as described in NIMH’s information on depression, and finding the right medication can take more than one attempt. Psychotherapy builds skills that last, and it also takes time.
For a person living with persistent thoughts of suicide, that interval is not neutral. It is a stretch of weeks during which the pain that prompted the call for help continues at full volume. Families describe it as waiting in a room with no clock: the emergency department can stabilize an acute crisis, an outpatient psychiatry appointment may be weeks out, and there is often little structured support in between. We have written elsewhere about how a rapid-intervention protocol can bridge that gap between emergency care and long-term treatment.
This is the specific problem that drew researchers to ketamine, not because it is novel and not because it replaces anything, but because it acts on a different timescale.
What the research says about ketamine and suicidal thoughts
Ketamine is a dissociative anesthetic that works primarily on NMDA receptors in the brain’s glutamate system rather than on serotonin. Dissociation here means a temporary sense of distance from the body, thoughts, or surroundings. That glutamate activity appears to promote neuroplasticity, the brain’s capacity to form new connections, which may be part of why relief can arrive in hours rather than weeks.
Three lines of evidence are worth knowing:
- Controlled trials in people with active suicidal ideation. A randomized trial led by Michael Grunebaum at Columbia compared a single ketamine infusion with midazolam in adults with major depression and clinically significant suicidal thoughts, and reported a greater reduction in those thoughts at 24 hours in the ketamine group.
- Pooled patient-level data. An individual participant data meta-analysis published in the American Journal of Psychiatry in 2018 by Samuel Wilkinson and colleagues drew on ten trials and found that a single infusion reduced suicidal ideation within one day, with effects still detectable at one week, and that the change was only partly explained by improvement in overall depression.
- Reviews of the broader literature. A 2023 peer-reviewed review of ketamine and esketamine for suicidal ideation in PubMed Central reaches a consistent conclusion: rapid, measurable reductions in suicidal thinking, with the durability of that response depending heavily on what follows the dose.
Real-world clinical data points in the same direction. Analyses of people treated with ketamine infusions in routine practice have reported meaningful reductions in suicidal ideation over the first weeks of treatment, with response tending to improve when the series is extended. We summarize that work on our page about ketamine treatment for suicidal ideation.
None of this makes ketamine a cure, and no responsible reading of the literature would call it one. What the evidence describes is a medicine that may lower the intensity of suicidal thinking quickly enough to change what is possible in the following weeks.
How the VA/DoD guideline frames it
Veterans Affairs has studied this question with unusual care, because suicide prevention is a central mission for the system. The VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide addresses ketamine and esketamine directly, and the Rocky Mountain MIRECC publishes a plain summary of recommendations 12 and 13 on its site.
The guideline’s posture is measured, and that is the useful part. It recognizes short-term reduction in suicidal ideation as a real effect while noting that evidence for sustained benefit is more limited, and it frames these medications as one component of care delivered alongside monitoring, safety planning, and ongoing treatment rather than as a standalone intervention. That is close to how we talk about it with members and with referring clinicians: the infusion can act as a catalyst, and the treatment plan is what turns a catalyst into change.
Veterans and first responders carry elevated risk in part because of trauma exposure, and post-traumatic stress disorder is one of the conditions most often underneath persistent suicidal thinking. A 2025 real-world study, “Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm” by MacConnel, Earleywine, and Radowitz, examined that population specifically. We cover the clinical picture on our page about ketamine for PTSD and trauma.
IV ketamine, Spravato, and what fits an urgent moment
Two medically supervised options exist in the United States today, and they are not interchangeable.
Spravato (esketamine) is a nasal spray approved by the FDA for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. Per the FDA’s prescribing information for Spravato, it is dispensed under a Risk Evaluation and Mitigation Strategy, which means it is administered in a certified setting with a monitoring period afterward. It is covered by many insurance plans. To find out whether you generally qualify and what the REMS requirements mean in practice, reach out to Nushama.
Intravenous ketamine is prescribed off-label for mood disorders, which is legal and common in medicine when evidence supports it. If the distinction between approved and off-label use is unfamiliar, we explain it in our post on ketamine’s FDA status and off-label use. An infusion gives the clinician precise control over dose and pace, and it can be slowed or stopped quickly. Onset of relief is often rapid. IV ketamine is generally private pay rather than an insurance benefit, so ask our care team what applies in your situation.
Our clinical view is that IV administration offers the most control and the most consistent depth of experience, which matters when someone is in acute distress. At-home lozenges and unsupervised protocols offer less control over dose, and no clinician is present in the room. For a person with suicidal thoughts, being observed by a medical team throughout is part of the treatment rather than an add-on to it.
Rapid relief opens a window. Integration decides what happens in it
The most common misunderstanding about fast-acting treatment is that speed alone is the point. A rapid drop in suicidal thinking creates a period when a person can sleep, eat, return phone calls, and engage in therapy they were too exhausted to use the week before.
That window closes if nothing fills it. Preparation before treatment, including intention setting and guidance on mindset, shapes what the experience yields. Integration afterward, with a licensed therapist or trained integration coach, helps turn insight into behavior: journaling, mindfulness, a revised safety plan, repair in relationships, and sometimes a change in drinking, since alcohol, anxiety, and depression tend to reinforce one another. Environment matters too, which is why we pay close attention to set and setting in every room where treatment happens.
Ketamine is also not appropriate for everyone. Screening at Nushama excludes people with uncontrolled hypertension, unstable heart disease, untreated thyroid disease, active mania, schizophrenia, or active psychotic symptoms, among other conditions. A medical assessment, including history, blood pressure, and EKG when indicated, comes before any decision about treatment.
Supporting someone this month
If a friend or family member tells you they are thinking about suicide, the most useful things you can do are unglamorous: stay calm, listen without judgment, ask directly and openly, help reduce access to lethal means, and stay with them while you connect to care. We go through these steps in more detail in our post on suicidal ideation and ketamine-assisted therapy, and SAMHSA maintains treatment locators and crisis resources on its behavioral health site.
Community is part of prevention as well. Isolation raises risk, and shared experience can lower it, which is why we host gatherings and educational events open to members and their families throughout the year. Veterans and first responders can ask about reduced pricing through our Hero’s Journey program, and monthly financial-based scholarships are available for members facing hardship.
Suicide Prevention Month works when awareness turns into a next step. If you are weighing options for yourself or someone you love, our care team can talk through screening, timing, and whether IV ketamine or Spravato fits the situation. Book a consultation whenever you are ready.